ClearPoint Neuro, Inc. (NASDAQ:CLPT – Get Free Report) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 1,280,000 shares, a decline of 8.6% from the March 15th total of 1,400,000 shares. Based on an average daily volume of 152,300 shares, the days-to-cover ratio is currently 8.4 days.
Wall Street Analysts Forecast Growth
Separately, Stifel Nicolaus reiterated a “buy” rating and set a $9.00 price objective (up from $8.00) on shares of ClearPoint Neuro in a report on Wednesday, March 13th.
View Our Latest Report on ClearPoint Neuro
Hedge Funds Weigh In On ClearPoint Neuro
ClearPoint Neuro Trading Down 0.5 %
NASDAQ CLPT opened at $5.58 on Wednesday. The company has a current ratio of 4.87, a quick ratio of 3.80 and a debt-to-equity ratio of 0.47. The business has a fifty day simple moving average of $6.76 and a 200 day simple moving average of $6.32. ClearPoint Neuro has a 12 month low of $4.05 and a 12 month high of $10.80. The firm has a market capitalization of $151.05 million, a P/E ratio of -6.13 and a beta of 0.89.
ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.03. The business had revenue of $6.81 million for the quarter, compared to analysts’ expectations of $6.40 million. ClearPoint Neuro had a negative net margin of 92.21% and a negative return on equity of 83.94%. On average, analysts predict that ClearPoint Neuro will post -0.75 EPS for the current fiscal year.
ClearPoint Neuro Company Profile
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
Recommended Stories
- Five stocks we like better than ClearPoint Neuro
- Buy P&G Now, Before It Sets A New All-Time High
- Prologis Stock Leading U.S. Logistics Boom
- What Do S&P 500 Stocks Tell Investors About the Market?
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
- Short Selling: How to Short a Stock
- Are We in a Bull Market? 4 Factors that Determine a Bull Market
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.